Niacin

apolipoprotein A1 ; Homo sapiens







25 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 29183962 Intestinal lymphatic HDL miR-223 and ApoA-I are reduced during insulin resistance and restored with niacin. 2018 Mar 3
2 27891663 Extended-release niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial. 2017 May 1
3 24285582 Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus. 2014 Feb 2
4 24956528 Niacin decreases leukocyte myeloperoxidase: mechanistic role of redox agents and Src/p38MAP kinase. 2014 Aug 4
5 22990043 Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol. 2013 Mar 1
6 24079282 Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. 2013 Sep-Oct 1
7 22389325 Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells. 2012 May 3
8 22500948 Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups. 2012 Jun 1 2
9 21664629 Nicotinic acid induces apolipoprotein A-I gene expression in HepG2 and Caco-2 cell lines. 2011 Dec 14
10 18602814 Effects of niacin and chromium on the expression of ATP-binding cassette transporter A1 and apolipoprotein A-1 genes in HepG2 cells. 2009 Apr 2
11 19166694 Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia. 2009 Feb 1 1
12 19797938 Niacin promotes cholesterol efflux through stimulation of the PPARgamma-LXRalpha-ABCA1 pathway in 3T3-L1 adipocytes. 2009 3
13 18375237 Mechanism of action of niacin. 2008 Apr 17 6
14 18566298 Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. 2008 Sep 3
15 18047854 Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? 2007 Dec 3 3
16 17319473 Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study. 2006 1
17 15539964 Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia. 2004 Fall 1
18 15539965 The effects of niacin on lipoprotein subclass distribution. 2004 Fall 1
19 12637338 Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. 2003 May 1 1
20 12767421 Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. 2003 Jun 1 1
21 14605511 Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. 2003 Fall 1
22 11701466 Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. 2001 Nov 1
23 9351367 Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. 1997 Oct 8
24 6403042 Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic properties and response to drug therapy. 1983 Apr 13 1
25 221531 Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. 1979 May 5